|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-2-3
|
|
pubmed:abstractText |
We have shown previously that tumor infiltration by FOXP3+ regulatory T cells (Treg) is associated with increased relapse and shorter survival of patients with both in situ and invasive breast cancer. Because estrogen regulates Treg numbers in mice and promotes the proliferation of human Tregs, we hypothesized that blocking estrogen receptor-alpha signaling would abrogate Tregs and be associated with response to hormonal therapy and increased survival.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AgugginiSergioS,
pubmed-author:AlleviGiovanniG,
pubmed-author:BanhamAlison HAH,
pubmed-author:BatesGaynorG,
pubmed-author:BerrutiAlfredoA,
pubmed-author:BersigaAlessandraA,
pubmed-author:BonardiSimoneS,
pubmed-author:BottiniAlbertoA,
pubmed-author:BrizziMaria PMP,
pubmed-author:CampoLeticiaL,
pubmed-author:DogliottiLuigiL,
pubmed-author:FoxStephen BSB,
pubmed-author:GeneraliDanieleD,
pubmed-author:HarrisAdrian LAL,
pubmed-author:MilaniManuelaM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1046-51
|
|
pubmed:meshHeading |
pubmed-meshheading:19188178-Aged,
pubmed-meshheading:19188178-Aged, 80 and over,
pubmed-meshheading:19188178-Aromatase Inhibitors,
pubmed-meshheading:19188178-Breast Neoplasms,
pubmed-meshheading:19188178-Cell Count,
pubmed-meshheading:19188178-Forkhead Transcription Factors,
pubmed-meshheading:19188178-Humans,
pubmed-meshheading:19188178-Middle Aged,
pubmed-meshheading:19188178-Nitriles,
pubmed-meshheading:19188178-Predictive Value of Tests,
pubmed-meshheading:19188178-Prognosis,
pubmed-meshheading:19188178-T-Lymphocytes, Regulatory,
pubmed-meshheading:19188178-Treatment Outcome,
pubmed-meshheading:19188178-Triazoles
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
|
|
pubmed:affiliation |
Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
